<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509636</url>
  </required_header>
  <id_info>
    <org_study_id>HR-FZPL-Ⅰb-OC</org_study_id>
    <nct_id>NCT03509636</nct_id>
  </id_info>
  <brief_title>A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer</brief_title>
  <official_title>An Open-Label Study to Assess the Efficacy And Safety of Poly(ADP-ribose) Polymerase Inhibitor Fluzoparib（SHR3162）in Patients With Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and BRCA1/2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP&#xD;
      1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine&#xD;
      diphosphate [ADP] ribose polymerase (PARP) 1/2 being developed for treatment of&#xD;
      BRCA1/2-mutant solid tumor. The tolerability, safety and PK of fluzoparib has been evaluated&#xD;
      in Phase 1 study. An oral formulation is the focus of current development efforts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">July 23, 2020</completion_date>
  <primary_completion_date type="Actual">August 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR by RECIST v1.1</measure>
    <time_frame>every 8 weeks (±7 days) of treatment</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>study data collection expected to last for ~2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>expected to last for ~2 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by GCIG CA-125</measure>
    <time_frame>every 8 weeks (±7 days) of treatment expected to last for ~2 years</time_frame>
    <description>Response rate per GCIG CA-125</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>study data collection expected to last for ~2 years</time_frame>
    <description>Overall suvival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, clinical laboratory abnormalities, and dose modifications</measure>
    <time_frame>Every day starting with signing of consent until 30 days after discontinuation of treatment</time_frame>
    <description>per CTC AE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough (Cmin) level of fluzoparib concentrations</measure>
    <time_frame>Cycle 1 to cycle 4(each cycle is 28 days)</time_frame>
    <description>Cssmin of fluzoparib concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluzoparib capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Fluzoparib capsule will be given twice daily orally</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>SHR-3162</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of high grade serous or Grade 2/3 endometrioid&#xD;
             epithelial ovarian, fallopian tube, or primary peritoneal cancer；&#xD;
&#xD;
          -  Confirmed documented BRCA1/2 mutation;&#xD;
&#xD;
          -  Received 2~4 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance&#xD;
             therapies administered as single agent treatment will not count as a chemotherapy&#xD;
             regimen；&#xD;
&#xD;
          -  Relapsed/progressive disease as confirmed by radiologic assessment；&#xD;
&#xD;
          -  Have measurable disease as defined by RECIST v1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous treatment with a PARP inhibitor;&#xD;
&#xD;
          -  Patient with any other malignancy which has been active or treated within the previous&#xD;
             5 years;&#xD;
&#xD;
          -  Patients with symptomatic uncontrolled brain metastases;&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

